NCT01789060

p-AKT Expression on Clinical Outcomes in Malignant Lymphoma

The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 262 (actual)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 17 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

Detailed description

Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B \[PKB\]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers. However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.

Conditions

• Malignant Lymphoma
• P13K-AKT Pathway Deregulation

Interventions

Type	Name	Description
OTHER	p-AKT immunohistochemical staining	p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides

Timeline

• Start date: 2012-12-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2013-02-11
• Last updated: 2013-02-11

Locations

1 site across 1 country: South Korea